Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder

References

• Styczynski J, Einsele H, Gil L, . Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009;11:383–392.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kosugi I, Terada T, . A case of Epstein-Barr virus associated post-transplant lymphoproliferative disorder with CNS involvement: pathological findings at both biopsy and autopsy. Neuropathology 2011;31:440–445.
   PubMed Web of Science ®Google Scholar
• Aisa Y, Mori T, Nakazato T, . Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 2009;11:438–441.
   PubMed Web of Science ®Google Scholar
• Kittan NA, Beier F, Kurz K, . Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis 2011;13:524–530.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Gil L, Donnelly JP, . Use of rituximab for post-SCT EBV-PTLD: the final results of a retrospective EBMT study. Bone Marrow Transplant 2012;47(Suppl. 1): Abstract 291.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H, . Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009;43: 757–770.
   PubMed Web of Science ®Google Scholar
• Martelius T, Lappalainen M, Palomaki M, . Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fluid. BMC Infect Dis 2011;11:281.
   PubMed Web of Science ®Google Scholar
• Bonney DK, Htwe EE, Turner A, . Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012;58:459–461.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Manenti L, Mancini C, . EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient. Am J Transplant 2010; 10:947–951.
   PubMed Web of Science ®Google Scholar
• Nozzoli C, Bartolozzi B, Guidi S, . Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006;47:167–169.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Doolittle ND, Muldoon LL, . Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus 2006;21:E11.
   PubMedGoogle Scholar
• van de Glind G, de Graaf S, Klein C, . Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008;50:886–888.
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Wiklund T, Collan J, . Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001;42:731–738.
   PubMed Web of Science ®Google Scholar
• Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, . Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009;144:794–795.
   PubMed Web of Science ®Google Scholar
• Schulz H, Pels H, Schmidt-Wolf I, . Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004;89:753–754.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L, . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350–1356.
   PubMed Web of Science ®Google Scholar
• Liu CY, Teng HW, Lirng JF, . Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 2008;49:2018–2021.
   PubMed Web of Science ®Google Scholar
• Kordelas L, Trenschel R, Koldehoff M, . Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 2008;31:691–693.
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Petroni G, Lopes MB, . Primary central nervous system post-transplantation lymphoproliferative disorder: an international primary central nervous system lymphoma collaborative group report. Cancer 2010;116:863–870.
   PubMed Web of Science ®Google Scholar
• Stephan JL, Le Deist F, Blanche S, . Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 1992;54: 246–249.
   PubMed Web of Science ®Google Scholar